<DOC>
	<DOCNO>NCT02121028</DOCNO>
	<brief_summary>The objective study determine mechanism stroke patient Intracranial Atherosclerotic Disease ( IAD ) specifically evaluate limitation antegrade flow stenotic artery , distal tissue perfusion affect territory , artery-to-artery embolism . The hypothesis non-invasive imaging biomarkers stratify stroke risk distinguish mechanism IAD . This prospective multicenter study enroll 175 patient recently symptomatic high-grade IAD . Patients study within 21 day index event ( allow appropriate time arrange diverse image modality ) , follow advanced neuroimaging technique elucidate mechanism recurrent ischemia : - Quantitative magnetic resonance imaging ( QMRA ) ass volumetric flow rate stenotic artery . - Magnetic resonance perfusion weight imaging ( PWI-MRI ) determine distal tissue perfusion . - Vasomotor reactivity Transcranial Doppler use breath-holding technique ( BHI-TCD ) ass compensatory flow characteristic territory distal affected artery ; - Transcranial Doppler embolic signal monitoring evaluate artery-to-artery embolism reflect plaque instability . Patients receive standardize medical management effectiveness blood pressure , lipid , glycemic control monitor . The primary outcome recurrent stroke territory stenotic artery 1-year follow-up period ; secondary outcome : ) new asymptomatic ischemic lesion MRI distribution stenotic artery 6-8 week , b ) transient ischemic attack ( TIA ) distribution stenotic artery 1-year follow-up period . Patients recruit various site train certified image technique employ . Raw image data interpret centrally .</brief_summary>
	<brief_title>Mechanisms Early Recurrence Intracranial Atherosclerotic Disease</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<criteria>1 . Stroke define symptom last &gt; 24 hour associate image evidence acute ischemia distribution stenotic vessel CT MRI . 2 . Eligible TIA define transient neurological symptom last &lt; 24 hour , need : 1. accompany DWI abnormality distribution stenotic artery ; 2. multiple ( â‰¥2 ) , stereotype event associated unequivocal ischemic symptom ( weakness , aphasia ) , attribute symptomatic artery . 3 . IAD involve intracranial carotid , middle cerebral , intracranial vertebral basilar artery . 4 . Stenosis 7099 % quantified digital subtraction angiography ( DSA ) , CT angiographyCTA MR angiographyMRA test . DSA require use obtain part clinical care . The criteria 7099 % : 1 . CTA DSA : measured 7099 % stenosis WASID criterion ( percent stenosis = ( 1 [ diameter stenosis/diameter normal ] ) x 100 % . 2 . MRA : measured 7099 % stenosis presence flow gap . 5 . Age &gt; 30 ; 3049 year age must also presence establish atherosclerotic disease another vascular bed ( coronary , extracranial carotid , peripheral ) presence 2 risk factor ( hypertension , diabetes mellitus , hyperlipidemia , tobacco abuse within last 2 year ) . 6 . Enrollment within 21 day symptom onset completion study image test within 21 day index event ( stroke TIA ) . 7 . Provide informed consent participation study . 1 . Other cause stroke : atrial fibrillation , acute anterior wall STelevation myocardial infarction &lt; 30days , mitral stenosis , mechanical valve , intracardiac thrombus vegetation , dilate cardiomyopathy ejection fraction &lt; 30 % , proximal extracranial carotid vertebral stenosis &gt; 50 % . 2 . Contraindications MRI , include MRincompatible metallic implant , implant electronic device , potentially mobile ferromagnetic material , pregnancy ( woman fertile age negative pregnancy test ) , lactation , morbid obesity , severe claustrophobia . 3 . Renal impairment define either creatinine level &gt; 1.5 mg/dL glomerular filtration rate ( GFR ) &lt; 30 mL/min/1.73 m2 . 4 . Known allergy gadolinium . 5 . Unable obtain informed consent patient legally authorize representative . 6 . Severe behavioral social problem may interfere conduct study . 7 . In investigator 's opinion , patient unlikely return follow visit complete study . 8 . Participation drug device clinical trial within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Intracranial Atherosclerotic Disease</keyword>
	<keyword>Stroke</keyword>
	<keyword>Transient Ischemic Attack</keyword>
	<keyword>Imaging</keyword>
</DOC>